Multiple Myeloma Market Projected to Grow Significantly, USD 53.52 Billion Revenue Predicted, Claims AMR

The multiple myeloma market size was valued at $19,666.74 million in 2021, and is projected to reach $53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031.

• Market Size By 2031 USD 53.5 billion
• Growth Rate CAGR of 10.5%
• Forecast period 2021 – 2031
• Report Pages 411

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝒕𝒉𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 𝑯𝒆𝒓𝒆-

https://www.alliedmarketresearch.com/request-sample/3725

Impact of Covid-19 on Multiple Myeloma Market: 

he global multiple myeloma market faced significant challenges during the outbreak of COVID-19, as social distancing measures resulted in the suspension of numerous clinical trials. The pandemic-induced scarcity of medical professionals, insufficient funding, and widespread lockdowns contributed to a surge in patients experiencing delays in accessing crucial treatments. Compounding these issues, disruptions in the supply chain led to a reduced availability of medications for multiple myeloma.

Additionally, research and development activities were severely hampered by the pandemic, causing a slowdown in the creation of new therapies and treatments for multiple myeloma. Despite these setbacks, the global market for multiple myeloma has shown signs of recovery in the post-pandemic period.

In 2021, the hospitals segment claimed the largest share, contributing to nearly two-thirds of the total revenue in the global multiple myeloma market. This segment is poised to maintain its leadership position throughout the forecast period, while also exhibiting the fastest Compound Annual Growth Rate (CAGR) of 10.7%. The study also evaluated the clinics and others segments.

 

𝑯𝒂𝒗𝒆 𝑨𝒏𝒚 𝑸𝒖𝒆𝒓𝒚? 𝑨𝒔𝒌 𝑶𝒖𝒓 𝑬𝒙𝒑𝒆𝒓𝒕 @: https://www.alliedmarketresearch.com/purchase-enquiry/3725

 

Regarding disease type, the active multiple myeloma segment dominated in 2021, capturing over four-fifths of the global market revenue. It is projected to sustain its market dominance in terms of revenue during the forecast period, with the same segment expected to demonstrate the fastest CAGR of 10.6%. The report also delves into the smoldering multiple myeloma segment.

In terms of regional distribution, North America secured the largest share in 2021, representing over one-third of the total multiple myeloma market revenue. It is anticipated to maintain its dominant position by 2031. Conversely, the Asia-Pacific region is poised to showcase the swiftest CAGR of 11.2% throughout the forecast period. The report also covers insights on Europe and LAMEA.

 

𝐓op Multiple Myeloma 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

• Sanofi
• Takeda Pharmaceutical Company Ltd
• AbbVie Inc
• Pfizer Inc.
• Novartis AG
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries
• Johnson & Johnson
• Amgen Inc.

 

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

UK IVF Market https://www.alliedmarketresearch.com/uk-ivf-market

Cancer Supportive Care Drugs Market https://www.alliedmarketresearch.com/cancer-supportive-care-drugs-market-A07133

 

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

 

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com